Future of diagnostics : personal genetics services due for explosive growth
<?xml version="1.0" encoding="UTF-8"?><modsCollection xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-8.xsd">
<mods version="3.8">
<titleInfo>
<title>Future of diagnostics</title>
<subTitle>: personal genetics services due for explosive growth</subTitle>
</titleInfo>
<name type="personal" usage="primary" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20170014812">
<namePart>Wylie, Craig</namePart>
<nameIdentifier>MAPA20170014812</nameIdentifier>
</name>
<name type="corporate" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080440602">
<namePart>Arthur D. Little</namePart>
<nameIdentifier>MAPA20080440602</nameIdentifier>
</name>
<typeOfResource>text</typeOfResource>
<originInfo>
<place>
<placeTerm type="code" authority="marccountry">usa</placeTerm>
</place>
<dateIssued encoding="marc">2017</dateIssued>
<issuance>monographic</issuance>
<place>
<placeTerm type="text">Madrid</placeTerm>
</place>
<publisher>Arthur D. Little</publisher>
<dateIssued>cop. 2017</dateIssued>
</originInfo>
<language>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<form authority="marcform">print</form>
<extent>12 p.</extent>
</physicalDescription>
<abstract displayLabel="Summary">Access to genetic information is becoming critical to the effectiveness of a new wave of medical treatments that are becoming available now. Personalized genetic services companies will act as a disruptive forces that are consumerizing genomic testing and driving rapid transformation of an industry that we expect to become a major force in personalized medicine. In this report, we consider how large this industry is likely to get in the next 10 years and start to evaluate how pharmaceutical companies, payers, providers and medtech companies will be impacted by the shift. We believe the emergence of ever cheaper testing technology means manufacturers can enhance clinical trials, payers can be selective in authorizing treatment payouts, and patients can have more confidence in outcomes</abstract>
<note type="statement of responsibility">Craig Wylie</note>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080591885">
<topic>Medicina preventiva</topic>
</subject>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080547424">
<topic>Genética</topic>
</subject>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080557850">
<topic>Diagnóstico</topic>
</subject>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080586546">
<topic>Nuevas tecnologías</topic>
</subject>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080591526">
<topic>Información privada</topic>
</subject>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080588533">
<topic>Tratamiento médico</topic>
</subject>
<classification authority="">931</classification>
<recordInfo>
<recordContentSource authority="marcorg">MAP</recordContentSource>
<recordCreationDate encoding="marc">171107</recordCreationDate>
<recordChangeDate encoding="iso8601">20171107133719.0</recordChangeDate>
<recordIdentifier source="MAP">MAP20170035831</recordIdentifier>
<languageOfCataloging>
<languageTerm type="code" authority="iso639-2b">spa</languageTerm>
</languageOfCataloging>
</recordInfo>
</mods>
</modsCollection>